Non-alcoholic fatty liver disease pathogenesis: the present and the future
- PMID: 19223251
- DOI: 10.1016/j.dld.2009.01.004
Non-alcoholic fatty liver disease pathogenesis: the present and the future
Abstract
Non-alcoholic fatty liver disease is the clinical hepatic expression of metabolic syndrome. The prevalence of non-alcoholic fatty liver disease is around 20-30%, and with a rapid increase in the metabolic risk factors in the general population, non-alcoholic fatty liver disease has become the most common cause of liver disease worldwide. A fraction (20-30%) of non-alcoholic fatty liver disease patients develop a potentially progressive hepatic disorder, namely non-alcoholic steatohepatitis, leading to end-stage liver disease. The pathogenesis of non-alcoholic fatty liver disease is not entirely understood, and even if insulin resistance is a major pathogenetic key, many other factors are implicated in both liver fat accumulation and disease progression to non-alcoholic steatohepatitis. In this review we aim to examine the literature, principally concerning human non-alcoholic fatty liver disease pathogenesis, and to identify the newest, most promising clinical and basic research data.
Similar articles
-
Non-alcoholic steatohepatitis and metabolic syndrome.Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):637-42. doi: 10.1097/01.mco.0000241677.40170.17. Curr Opin Clin Nutr Metab Care. 2006. PMID: 16912563 Review.
-
Review article: the metabolic syndrome and non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:31-6. doi: 10.1111/j.1365-2036.2005.02592.x. Aliment Pharmacol Ther. 2005. PMID: 16225469 Review.
-
Recent concepts in non-alcoholic fatty liver disease.Diabet Med. 2005 Sep;22(9):1129-33. doi: 10.1111/j.1464-5491.2005.01748.x. Diabet Med. 2005. PMID: 16108837 Review.
-
[Non-alcoholic fatty liver disease--new view].Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Pol Merkur Lekarski. 2008. PMID: 18702346 Review. Polish.
-
Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis.Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:44-7. doi: 10.1111/j.1365-2036.2005.02595.x. Aliment Pharmacol Ther. 2005. PMID: 16225472 Review.
Cited by
-
Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.J Pathol. 2017 Jan;241(1):36-44. doi: 10.1002/path.4829. Epub 2016 Nov 22. J Pathol. 2017. PMID: 27757953 Free PMC article. Review.
-
TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis.Lipids Health Dis. 2021 Apr 20;20(1):39. doi: 10.1186/s12944-021-01458-0. Lipids Health Dis. 2021. PMID: 33879188 Free PMC article.
-
Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease.J Med Ultrason (2001). 2023 Apr;50(2):187-195. doi: 10.1007/s10396-023-01293-z. Epub 2023 Feb 18. J Med Ultrason (2001). 2023. PMID: 36801991
-
Uneven acute non-alcoholic fatty change of the liver after percutaneous transhepatic portal vein embolization in a patient with hilar cholangiocarcinoma - a case report.BMC Gastroenterol. 2017 Dec 6;17(1):144. doi: 10.1186/s12876-017-0715-5. BMC Gastroenterol. 2017. PMID: 29207941 Free PMC article.
-
Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B.Sci Rep. 2021 Jan 12;11(1):655. doi: 10.1038/s41598-020-80709-z. Sci Rep. 2021. PMID: 33436935 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources